Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Another BACE inhibitor fails in phase III trials
  2. Deals this week: InSphero, Ind-Swift Laboratories, Sage Therapeutics
  3. Deals this week: Deciphera Pharmaceuticals, Tricida, ENYO Pharma
  4. M&As this week: Tongyang, Glenmark Pharmaceuticals, Leerink Revelation Partners
  5. Deals this week: HitGen, Lion TCR, Information Medical

Latest Content

Another BACE inhibitor fails in phase III trials

On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the decision to terminate AMARANTH (NCT02245737) and the DAYBREAK-ALZ (NCT02783573) trials after an independent data monitoring committee concluded they were unlikely to meet primary endpoints based on interim analysis. The related AMARANTH extension trial (NCT02972658) will also be discontinued. This termination is preceded by recent failures of BACE inhibitors in late stage clinical development for the treatment of AD.

ImmunXperts Company Video

ImmunXperts is a young company with rich history. It has a flexible development team, and focuses on quality and innovation.

Laser Microdissection with PALM MicroBeam Technology

Its laser microdissection with PALM MicroBeam technology allows for contact-free and uncontaminated specimen collection from specific compartments of skin and hair follicles for use in next-generation sequencing analysis.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top